CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Core Insights - Science 37 Holdings, Inc. is enhancing patient access to clinical trials, achieving significant enrollment figures in collaboration with a clinical-stage drug development company focused on systemic neuro-immune disorders [2][5] - The company utilizes its proprietary Metasite™ and Patient Recruitment solutions to broaden the recruitment pool beyond traditional geographic limitations, which is crucial for rare disease research [3][4] Enrollment Achievements - Science 37 contributed to 21% of all randomized study participants from September 2022 to April 2024, surpassing its contracted enrollment goal [8] - The average enrollment rate achieved by Science 37 was 1 patient per month, compared to only 0.1 patients per month at each of the 51 traditional study sites [8] Technology and Solutions - The Metasite™ and Patient Recruitment solutions are designed to enhance clinical trial enrollment by rigorously qualifying patients and expanding access beyond traditional sites [4][6] - Science 37's approach is supported by a proprietary technology stack and in-house medical and operational experts, ensuring quality through standardized workflows [4]